Preliminary Final Report and Annual Report – Year Ended 31 March 2022 – 1stOncology™: Cancer Intelligence Service

On May 30, 2022 Amplia Therapeutics Limited (ASX: ATX) reported the following (Press release, Amplia Therapeutics, MAY 30, 2022, View Source [SID1234615220]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

• Appendix 4E Preliminary Final Report YE 31 March 2022
• Annual Report – Year Ended 31 March 2022
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Preliminary Final Report and Annual Report – Year Ended 31 March 2022